Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean bis taurus bone?
Displaying drugs 101 - 125 of 425 in total
Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is...
Approved
Investigational
Cupric sulfate is a salt created by treating cupric oxide with sulfuric acid. This forms as large, bright blue crystals containing five molecules of water (CuSO4∙5H2O) and is also known as blue vitriol. The anhydrous salt is created by heating the hydrate to 150 °C (300 °F). Cupric sulfate is...
Approved
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also...
Approved
Investigational
Matched Mixtures name: … One A Day Bone Builder …
Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.
Approved
Investigational
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene,...
Approved
Investigational
Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to...
Approved
Investigational
Aluminum zirconium octachlorohydrex gly is complex that consists of aluminum zirconium octachlorohydrate and glycine. It is an active antiperspirant agent , . It diffuses into the sweat pores and prevents perspiration (sweat) from leaving the pores. The anhydrous form of the compound also has water-absorbing properties. Currently, the FDA allows...
Approved
Matched Products: … Bone Collector …
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less...
Approved
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it...
Approved
Investigational
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive...
Approved
Investigational
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local...
Approved
Vet approved
Matched Mixtures name: … Jamshidi Bone Marrow Biopsy Tray …
Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was...
Approved
Investigational
Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptors. Unlike other more common GABAA positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synaptic and extrasynaptic GABAA conductance due to binding to a non-benzodiazepine site on the receptor.[A260776,A260786] Zuranolone was...
Approved
Experimental
Bos taurus skin or pelt is used in allergenic testing.
Approved
Matched Name: … Bos taurus skin …
Matched Description: … Bos taurus skin or pelt is used in allergenic testing. …
Matched Products: … Bos Taurus Skin …
Elapegademase is a PEGylated recombinant adenosine deaminase. It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues. Elapegademase is generated in E. coli,...
Approved
Matched Synonyms: … (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, ... (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA …
Skim milk allergenic extract is used in allergenic testing.
Approved
Matched Synonyms: … Bos taurus milk, fat removed …
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium...
Approved
Investigational
Matched Description: … 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone ... The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide ... the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone
Matched Categories: … Pain Palliation (Bone Seeking Agents) …
Matched Products: … T-BONE KAEF …
Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.
Approved
Experimental
Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid,...
Approved
Investigational
Vet approved
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have shown that strontium ranelate can slow down the progression of osteoarthritis of the knee. This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and,...
Approved
Withdrawn
Matched Description: … and, simultaneously, reduces the resorption of bone by osteoclasts. ... It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe ... clinical studies demonstrate the ability of strontium ranelate to improve and strengthen intrinsic bone
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid...
Approved
Matched Description: … metastases from solid tumors, and Paget’s disease of bone. ... to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA...
Approved
Investigational
Matched Description: … [L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss …
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss ... It further received additional indication approval to increase bone mass in men at high risk for fracture …
Matched Categories: … Bone Density Conservation Agents ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Displaying drugs 101 - 125 of 425 in total